Suppr超能文献

从慢性淋巴细胞白血病小鼠模型产生的细胞系表现出组成性的Btk和Akt信号传导。

Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling.

作者信息

Singh Simar Pal, Pillai Saravanan Y, de Bruijn Marjolein J W, Stadhouders Ralph, Corneth Odilia B J, van den Ham Henk Jan, Muggen Alice, van IJcken Wilfred, Slinger Erik, Kuil Annemieke, Spaargaren Marcel, Kater Arnon P, Langerak Anton W, Hendriks Rudi W

机构信息

Department of Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands.

Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.

出版信息

Oncotarget. 2017 May 26;8(42):71981-71995. doi: 10.18632/oncotarget.18234. eCollection 2017 Sep 22.

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature CD5 B cells in blood. Spontaneous apoptosis of CLL cells has hampered in-depth investigation of CLL pathogenesis. Here we describe the generation of three monoclonal mouse cell lines, EMC2, EMC4 and EMC6, from the CLL mouse model based on sporadic expression of SV40 large T antigen. The cell lines exhibit a stable CD5CD43IgMCD19 CLL phenotype in culture and can be adoptively transferred into mice. RNA-seq analysis revealed only minor differences between the cell lines and their primary tumors and suggested that NF-κB and mTOR signaling pathways were involved in cell line outgrowth. survival and proliferation was dependent on constitutive phosphorylation of Bruton's tyrosine kinase (Btk) at Y551/Y223, and Akt(S473). Treatment of the cell lines with small molecule inhibitors specific for Btk (ibrutinib) or PI3K (idelalisib), which is upstream of Akt, resulted in reduced viability, proliferation and fibronectin-dependent cell adhesion. Treatment of cell line-engrafted mice with ibrutinib was associated with transient lymphocytosis, reduced splenomegaly and increased overall survival. Thus, by generating stable cell lines we established a novel platform for and investigation of CLL signal transduction and treatment modalities.

摘要

慢性淋巴细胞白血病(CLL)的特征是血液中成熟CD5 B细胞的积累。CLL细胞的自发凋亡阻碍了对CLL发病机制的深入研究。在此,我们描述了基于SV40大T抗原的散在表达,从CLL小鼠模型中生成三种单克隆小鼠细胞系EMC2、EMC4和EMC6。这些细胞系在培养中表现出稳定的CD5CD43IgMCD19 CLL表型,并且可以过继转移到小鼠体内。RNA测序分析揭示了细胞系与其原发性肿瘤之间仅存在微小差异,并表明NF-κB和mTOR信号通路参与了细胞系的生长。细胞的存活和增殖依赖于布鲁顿酪氨酸激酶(Btk)在Y551/Y223位点以及Akt(S473)的组成型磷酸化。用对Btk(依鲁替尼)或PI3K(idelalisib,Akt上游分子)具有特异性的小分子抑制剂处理细胞系,导致细胞活力、增殖以及纤连蛋白依赖性细胞黏附降低。用依鲁替尼处理细胞系移植小鼠会导致短暂的淋巴细胞增多、脾肿大减轻以及总生存期延长。因此,通过生成稳定的细胞系,我们建立了一个用于研究CLL信号转导和治疗方式的新平台。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ab6/5641105/74c3332d828f/oncotarget-08-71981-g001.jpg

相似文献

1
Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling.
Oncotarget. 2017 May 26;8(42):71981-71995. doi: 10.18632/oncotarget.18234. eCollection 2017 Sep 22.
4
Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL.
Blood Adv. 2021 Aug 24;5(16):3134-3146. doi: 10.1182/bloodadvances.2020003821.
5
BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Int Rev Immunol. 2013 Aug;32(4):358-76. doi: 10.3109/08830185.2013.786711. Epub 2013 Apr 25.
7
Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Semin Oncol. 2016 Apr;43(2):251-9. doi: 10.1053/j.seminoncol.2016.02.008. Epub 2016 Feb 9.
9
Aspartic Aminopeptidase Is a Novel Biomarker of Aggressive Chronic Lymphocytic Leukemia.
Cancers (Basel). 2020 Jul 12;12(7):1876. doi: 10.3390/cancers12071876.
10
BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):125-34. doi: 10.1182/asheducation-2014.1.125. Epub 2014 Nov 18.

引用本文的文献

1
Phosphatidylcholine-specific B cells are enriched among atypical CD11c and CD21 memory B cells in antiphospholipid syndrome.
Front Immunol. 2025 Jun 3;16:1585953. doi: 10.3389/fimmu.2025.1585953. eCollection 2025.
2
From development to clinical success: the journey of established and next-generation BTK inhibitors.
Invest New Drugs. 2025 Apr;43(2):377-393. doi: 10.1007/s10637-025-01513-y. Epub 2025 Feb 27.
3
CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity.
Mol Ther Oncol. 2024 Jun 24;32(3):200841. doi: 10.1016/j.omton.2024.200841. eCollection 2024 Sep 19.
4
B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia.
Front Oncol. 2024 Feb 26;14:1339620. doi: 10.3389/fonc.2024.1339620. eCollection 2024.
6
Immune ageing at single-cell resolution.
Nat Rev Immunol. 2022 Aug;22(8):484-498. doi: 10.1038/s41577-021-00646-4. Epub 2021 Nov 23.
7
Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.
Eur J Immunol. 2021 Sep;51(9):2251-2265. doi: 10.1002/eji.202048968. Epub 2021 Aug 16.
9
Aberrantly expressed Bruton's tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells.
Cell Oncol (Dordr). 2020 Dec;43(6):1067-1084. doi: 10.1007/s13402-020-00541-5. Epub 2020 Jul 23.
10
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Cancers (Basel). 2020 Apr 9;12(4):927. doi: 10.3390/cancers12040927.

本文引用的文献

1
Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.
Oncotarget. 2016 Oct 25;7(43):70623-70638. doi: 10.18632/oncotarget.12139.
2
Cancer treatment and survivorship statistics, 2016.
CA Cancer J Clin. 2016 Jul;66(4):271-89. doi: 10.3322/caac.21349. Epub 2016 Jun 2.
3
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
Blood. 2016 Jul 28;128(4):574-83. doi: 10.1182/blood-2016-02-700328. Epub 2016 May 27.
4
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7.
5
Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLL.
Leuk Res. 2016 Jan;40:54-9. doi: 10.1016/j.leukres.2015.10.008. Epub 2015 Oct 19.
6
Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line.
PLoS One. 2015 Jun 25;10(6):e0130195. doi: 10.1371/journal.pone.0130195. eCollection 2015.
7
HTSeq--a Python framework to work with high-throughput sequencing data.
Bioinformatics. 2015 Jan 15;31(2):166-9. doi: 10.1093/bioinformatics/btu638. Epub 2014 Sep 25.
8
The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia.
Semin Hematol. 2014 Jul;51(3):158-67. doi: 10.1053/j.seminhematol.2014.05.003. Epub 2014 May 15.
9
Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy.
Blood. 2014 Aug 14;124(7):1010-9. doi: 10.1182/blood-2014-05-577122. Epub 2014 Jul 8.
10
The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy.
Haematologica. 2014 Jul;99(7):1138-48. doi: 10.3324/haematol.2013.098384.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验